1,670
Views
3
CrossRef citations to date
0
Altmetric
Case Report

Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level

ORCID Icon & ORCID Icon
Pages 1599-1603 | Received 28 Aug 2020, Accepted 30 Oct 2020, Published online: 02 Mar 2021

References

  • Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–53. doi:10.1111/j.1365-2362.2007.01807.x. PMID: 17537151.
  • Bonadonna P, Scaffidi L. Hymenoptera anaphylaxis as a clonal mast cell disorder. Immunol Allergy Clin North Am. 2018;38:455–68. doi:10.1016/j.iac.2018.04.010. PMID: 30007463.
  • Sturm GJ, Varga EM, Roberts G, Mosbech H, Bilò MB, Akdis CA, Antolín-Amérigo D, Cichocka-Jarosz E, Gawlik R, Jakob T, et al. EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy. Allergy. 2018;73:744–64. doi:10.1111/all.13262. PMID: 28748641.
  • Michel J, Brockow K, Darsow U, Ring J, Schmidt-Weber CB, Grunwald T, Blank S, Ollert M. Added sensitivity of component-resolved diagnosis in hymenoptera venom-allergic patients with elevated serum tryptase and/or mastocytosis. Allergy. 2016;71:651–60. doi:10.1111/all.12850. PMID: 26836051.
  • Vos BJPR, van Anrooij B, van Doormaal JJ, Dubois AEJ, Oude Elberink JNG. Fatal anaphylaxis to yellow jacket stings in mastocytosis: options for identification and treatment of at-risk patients. J Allergy Clin Immunol Pract. 2017;5:1264–71. doi:10.1016/j.jaip.2017.03.019. PMID: 28499778.
  • Cifuentes L, Vosseler S, Blank S, Seismann H, Pennino D, Darsow U, Bredehorst R, Ring J, Mempel M, Spillner E, et al. Identification of hymenoptera venom-allergic patients with negative specific IgE to venom extract by using recombinant allergens. J Allergy Clin Immunol. 2014;133:909–10. doi:10.1016/j.jaci.2013.09.047. PMID: 24290287.
  • Bonadonna P, Gonzalez-de-Olano D, Zanotti R, Riccio A, De Ferrari L, Lombardo C, Rogkakou A, Escribano L, Alvarez-Twose I, Matito A, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract. 2013;1:474–78. doi:10.1016/j.jaip.2013.06.014. PMID: 24565619.
  • González de Olano D, Alvarez-Twose I, Esteban-López MI, Sánchez-Muñoz L, de Durana MD, Vega A, García-Montero A, González-Mancebo E, Belver T, Herrero-Gil MD, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol. 2008;121:519–26. doi:10.1016/j.jaci.2007.11.010. PMID: 18177694.
  • Verburg M, Oldhoff JM, Klemans RJ, Lahey-de Boer A, de Bruin-weller MS, Röckmann H, Sanders C, Bruijnzeel-Koomen CA, Pasmans SG, Knulst AC. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis. Eur Ann Allergy Clin Immunol. 2015;47:192–96. PMID: 26549336.
  • Gruzelle V, Ramassamy M, Bulai Lidiveanu C, Didier A, Mailhol C, Guilleminault L. Safety of ultra-rush protocols for hymenoptera venom immunotherapy in systemic mastocytosis. Allergy. 2018;73:2260–63. doi:10.1111/all.13557. PMID: 29984458.
  • Jarkvist J, Salehi C, Akin C, Gülen T. Venom immunotherapy in patients with clonal mast cell disorders: igG4 correlates with protection. Allergy. 2020;75:169–77. doi:10.1111/all.13980. PMID: 31306487.
  • Golden DBK. Venom Immunotherapy: questions and controversies. Immunol Allergy Clin North Am. 2020;40:59–68. doi:10.1016/j.iac.2019.09.002. PMID: 31761121.
  • Kors JW, van Doormaal JJ, de Monchy JG. Anaphylactoid shock following Hymenoptera sting as a presenting symptom of systemic mastocytosis. J Intern Med. 1993;233:255–58. doi:10.1111/j.1365-2796.1993.tb00984.x. PMID: 8450293.